Cospain Auriane, Dion Ludivine, Bidet Maud, Nyangoh Timoh Krystel, Quelin Chloé, Carton Isis, Lavillaureix Alinoe, Morcel Karine, Rollier Paul, Pasquier Laurent, Nouyou Bénédicte, Odent Sylvie, Guerrier Daniel, Launay Erika, Belaud Rotureau Marc-Antoine, Fradin Mélanie, Jaillard Sylvie, Lavoué Vincent
Clinical Genetics Department, CLAD Ouest CRDI, ERN ITHACA, Rennes University Hospital, Rennes, France.
Cytogenetics and Cell Biology Department, Rennes University Hospital, Rennes, France.
Acta Obstet Gynecol Scand. 2025 Mar;104(3):514-521. doi: 10.1111/aogs.14985. Epub 2024 Oct 9.
Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome with utero-vaginal aplasia is the most severe form of the Müllerian duct anomalies and can be associated with extra-genital abnormalities such as renal or skeletal anomalies, hearing loss, or cardiac defects. The past two decades have witnessed significant advances both in understanding the etiologies of MRKH and in the development of fertility treatments such as uterine transplantation. The present work aimed to determine the rate of women with MRKH syndrome who underwent optimal initial management (after comprehensive malformation assessment) and to establish the rate of patients eligible for uterine transplantation (i.e., those with a vaginal length ≥7 cm without reconstruction using a bowel segment, and an anti-Müllerian hormone level >1.5 ng/mL before 35 years).
Cohort study of 85 women with MRKH syndrome consulting in our tertiary center.
62.4% of women with MRKH syndrome had an exhaustive malformative evaluation according to the French guidelines (Protocole National de Diagnostic et de Soin [PNDS]), of which 76.5% had associated malformations (MRKH type II). Pedigree, when available, showed a family history of infertility or a urogenital tract spectrum anomaly in 60% of cases. Concerning the uterine transplantation selection criteria, when evaluated, 22.6% of women had an anti-Müllerian hormone level <1.5 ng/mL and 36% a vaginal length <7 cm. On the 21 women with complete evaluation of both primary and secondary outcomes, 14 of them would be eligible for a uterine transplantation program at the time of consultation according to the main inclusion criteria of uterine transplantation program.
Women with MRKH syndrome are often inadequately explored for associated malformations. Early assessment and monitoring of the ovarian reserve is key for fertility preservation, especially in the era of uterine transplantation.
伴有子宫阴道发育不全的迈耶-罗基坦斯基-库斯特-豪泽综合征(MRKH综合征)是苗勒管异常最严重的形式,可能与肾或骨骼异常、听力损失或心脏缺陷等生殖器外异常有关。在过去二十年中,在了解MRKH综合征的病因以及子宫移植等生育治疗方法的发展方面都取得了重大进展。本研究旨在确定接受最佳初始治疗(全面畸形评估后)的MRKH综合征女性的比例,并确定符合子宫移植条件的患者比例(即阴道长度≥7厘米且未使用肠段进行重建、35岁之前抗苗勒管激素水平>1.5纳克/毫升的患者)。
对在我们三级中心就诊的85例MRKH综合征女性进行队列研究。
根据法国指南(国家诊断与治疗协议[PNDS]),62.4%的MRKH综合征女性进行了详尽的畸形评估,其中76.5%伴有相关畸形(MRKH II型)。如有家族谱系,60%的病例显示有不孕或泌尿生殖道谱系异常的家族史。关于子宫移植选择标准,在进行评估时,22.6%的女性抗苗勒管激素水平<1.5纳克/毫升,36%的女性阴道长度<7厘米。在对主要和次要结局均进行全面评估的21名女性中,根据子宫移植项目的主要纳入标准,其中14名在咨询时符合子宫移植项目的条件。
MRKH综合征女性常未对相关畸形进行充分检查。早期评估和监测卵巢储备对于保留生育能力至关重要,尤其是在子宫移植时代。